Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis

Ronan Joseph Kelly, Thomas J Smith

Research output: Contribution to journalReview article

Original languageEnglish (US)
Pages (from-to)1814-1816
Number of pages3
JournalJournal of Thoracic Oncology
Volume11
Issue number11
DOIs
StatePublished - Nov 13 2016

Fingerprint

Cost-Benefit Analysis
Lung Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis. / Kelly, Ronan Joseph; Smith, Thomas J.

In: Journal of Thoracic Oncology, Vol. 11, No. 11, 13.11.2016, p. 1814-1816.

Research output: Contribution to journalReview article

@article{6d9e8f3c37094f4292c834f92aa7a12d,
title = "Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis",
author = "Kelly, {Ronan Joseph} and Smith, {Thomas J}",
year = "2016",
month = "11",
day = "13",
doi = "10.1016/j.jtho.2016.07.028",
language = "English (US)",
volume = "11",
pages = "1814--1816",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "11",

}

TY - JOUR

T1 - Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis

AU - Kelly, Ronan Joseph

AU - Smith, Thomas J

PY - 2016/11/13

Y1 - 2016/11/13

UR - http://www.scopus.com/inward/record.url?scp=84995899614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995899614&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.07.028

DO - 10.1016/j.jtho.2016.07.028

M3 - Review article

VL - 11

SP - 1814

EP - 1816

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 11

ER -